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population breakdown, survival rates, average costs of triple and quadruple HAART 
(Highly Active Antiretroviral Therapy) therapy, inpatient, outpatient care costs—HIV 
related HRG costs and excess cost ratio due to late presentation. Study follows stan-
dard good modeling practices by discounting, adjusting for survival, and considering 
multiple time horizons for analyses. UK data sources include: BHIVA, NHS, HPA and 
SOPHID. RESULTS: From 1995–2010 literature review yielded 126 publications 
related to late detection, of which 18 were included in our study design. The number 
of publications has rapidly increased over the last 12 months. Preliminary results 
suggest that 10% of HIV detection shift from late to early detection (2655 patients 
or 3.2% of Late HIV detection) would result in £20.3 million conservative savings 
just in the ﬁ rst year (keeping index multiplier scalar for HIV spread rate at zero). Over 
5-year term, such annual shift would result in 708.25 life-years saved or £14.2 million 
in additional savings. CONCLUSIONS: Enhanced testing to achieve earlier detection 
and initiation on HAART could potentially reduce overall costs of HIV medical care. 
Further research is required to determine additional budgetary implications of HIV 
comorbidity patterns.
PIN27
COST-EFFECTIVENESS ANALYSIS OF HPV VACCINATION AGAINST 
CERVICAL CANCER IN YOUNG ADULT WOMEN IN ITALY
La Torre G1, Gabutti G2, Cristoforoni P3, Bonanni P4, Amunni G4, Costa S5, Capri S6
1Sapienza University of Rome, Rome, Italy; 2University of Ferrara, Ferrara, Italy; 3National 
Institute for Cancer Research, IST Genova, Genova, Italy; 4University of Florence, Florence, 
Italy; 5St. Orsola-Malpighi University Hospital, Bologna, Italy; 6Cattaneo-LIUC University, 
Castellanza, Varese, Italy
OBJECTIVES: Human papillomavirus (HPV) has been implicated as a causal factor 
in cervical cancer (CC), the second most common cancer among women worldwide. 
Prophylactic vaccination against HPV-16/18 has been shown to be highly effective in 
preventing HPV related infections and pre-cancerous lesions. The aim of this study 
was to determine the potential clinical and economic impact of combining CC screen-
ing programme with HPV vaccination programme with the bivalent HPV-16/18 
vaccine in women aged 25 (when CC screening starts) compared to screening alone. 
METHODS: A Markov cohort model was adapted to the Italian setting. The model 
replicates the HPV infection natural history leading to CC and includes the effect of 
screening and vaccination. Based on the latest results of the PATRICIA clinical trial 
for the bivalent vaccine, the vaccine efﬁ cacy includes cross-protection against non-
vaccine HPV types 31/33/35/39/45/51/52/56/58/59. The vaccine efﬁ cacy in naïve girls 
and HPV-exposed women (>17-years old) was differentiated. Lifetime protection and 
90% vaccination coverage were assumed. Costing was analyzed from the perspective 
of the Italian health care system. Main outcomes are lifetime costs, QALYs, CC cases, 
deaths and ICER. Both costs and effects were discounted at 3% annually to calculate 
the ICER. RESULTS: The model shows that, compared to screening alone, vaccinating 
a single cohort of 330,000 women aged 25 would prevent over a lifetime 696 CC 
cases and 316 CC deaths (undiscounted) of which 131 and 59 respectively are due to 
cross-protection, with a discounted ICER of c33,918 per QALY gained. The ICER 
remains under the cost-effective threshold deﬁ ned by the WHO (between 1 and 
3xGDP/capita). CONCLUSIONS: Under the assumptions of the model, extending 
vaccination to young adult women post-HPV exposure could lead to a substantial 
reduction in CC and remains cost-effective in Italy compared with screening alone. 
Cross-protection would play an important role in this reduction.
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OBJECTIVES: Rotavirus is the leading cause of severe gastroenteritis in children under 
5 years. Two vaccines are currently available: RotaTeq® (Merck/Sanoﬁ  Pasteur MSD) 
and Rotarix® (GSK). Published economic models on rotavirus vaccination have pro-
duced contradicting results. We reviewed and critically appraised existing economic 
models. METHODS: The literature search covered worldwide cost-effectiveness 
models of RotaTeq® and Rotarix® published or presented at conferences until 
October 2009. We extracted information on model structures, input data (epidemiol-
ogy, vaccine efﬁ cacy, utilities, vaccination costs) and results. RESULTS: We identiﬁ ed 
44 publications referring to distinct cost-effectiveness analyses.18 used cost per QALY 
as primary outcome, providing 22 incremental cost-utility ratios (ICURs) for high-
income countries. Thirteen ICURs came from health authorities and 9 from manufac-
turers. While some European studies predicted cost-savings from societal perspective, 
the ICUR was estimated at up c160,000 per QALY for the UK, from NHS perspective. 
5 of 13 analyses from health authorities reported ICURs below c30,000 per QALY 
gained, compared to 7 of 9 studies from manufacturers. There were many differences 
between models, such as perspective, epidemiological inputs, vaccine efﬁ cacy and 
vaccination costs. However differences in results were mainly driven by assumptions 
related to estimation of QALYs: utility values, duration of symptoms, inclusion of 
quality of life burden for caregivers and for cases without medical attention. CON-
CLUSIONS: Results of cost-effectiveness analyses are highly variable due to uncer-
tainty surrounding epidemiological inputs, and most importantly to assumptions for 
deriving QALYs. Different choices were attributable to different value judgments, and 
to the difﬁ culty of measuring and valuing quality of life in children, which lead to a 
situation where neither manufacturers nor health authorities obtained valid utilities. 
There is currently no valid reference case for cost-utility analyses in paediatrics. More 
open communication and expertise sharing between authorities and manufacturers 
could lead to more reliable analyses.
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OBJECTIVES: Streptococcus pneumonia is associated with two invasive diseases 
(meningitis and bacteremia) and non-invasive disease (pneumococcal pneumonia), 
which has caused high morbidity and mortality in infants and the elderly in Taiwan. 
a cost-effectiveness analysis of pneumococcal conjugate vaccine (PCV 10) in Taiwan 
was conducted using transmission-dynamic model. METHODS: As static pharmaco-
economic model fails to account for vaccination-induced herd-immunity, we devel-
oped an age-structured multi-compartment dynamic model to estimate both economic 
and clinical impact of universal PCV10 vaccination over 10-year time horizon under 
health care system’s perspective in Taiwan. Model parameters such as economic and 
clinical burden of pneumococcal diseases in Taiwanese population, vaccine efﬁ cacy, 
utilities and demographic parameters were captured by retrospective population-based 
National Health Insurance Reimbursement Database (NHIRD), published sources, 
unpublished data, and assumptions made in consultation with clinical experts. Uni-
variate sensitivity analyses were conducted to test the robustness of model parameters. 
RESULTS: Assuming a four-dose schedule and 90% of vaccination coverage for both 
vaccines, universal infant vaccination with PCV10 would prevent 133 cases of IPD, 
122,476 cases of pneumococcal pneumonia and 3,857 deaths, an equivalent of 93,393 
life-years and leads to a net medical cost savings of NT$ 6,047.4 million, compared 
to no vaccination. At the current proposed price of NT$2,700 for PCV10, the incre-
mental cost-effectiveness ratio (ICER) is expected to be cost-effective with NT$106,362 
(US$3,324) per life-year gained. The program’s cost-effectiveness results are highly 
sensitive to the vaccine price and number of doses while not sensitive to uncertainty 
in disease incidence and costs of treatment. CONCLUSIONS: Universal pediatric 
PCV10 vaccination in Taiwan is estimated to have considerable impact on reducing 
the burden of pneumococcal diseases and expected to be cost-effective in payer’s 
perspective compared to no vaccination.
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OBJECTIVES: To assess the efﬁ ciency of daptomycin as ﬁ rst-line therapy (D) versus 
daptomycin as rescue therapy after failure of vancomycin (V+D) or linezolid (L+D) in 
gram-positive bacteremia treatment. METHODS: A cost-effectiveness analysis com-
paring the three therapeutic alternatives (D, V+D and L+D) was performed using data 
from a previous observational study (EUCORE). In the present sub-study, data on 19 
(D), 33 (V+D) and 19 (L+D) bacteremic patients were analyzed. Effectiveness was 
measured in terms of cure or clinical improvement. Costs were gathered from “BOT” 
and “e-salud” Spanish databases. Direct costs (medication and hospitalization) due to 
bacteremia were included. Costs are expressed in 2009 Euros. Patients were observed 
until either end of daptomycin therapy or exitus. a probabilistic multivariate sensitivity 
analysis was carried out. Dispersion was estimated using bootstrap (three alternative 
scenarios were considered in the simulations: 50%, 25% and 10% of the estimated 
dispersion) and Monte Carlo simulations were performed for both costs (log-normally 
distributed) and effectiveness (normally distributed) measures. RESULTS: Effective-
ness ﬁ gures: D: 84.2% (95%CI: 60.4%–96.6%); V+D: 87.9% (95%CI: 71.8%–
96.6%); L+D: 68.4% (95% CI: 43.5%–87.4%); pvalue = 0.206 (Chi2). Average costs 
per treated patient: D: c6672.8 (95%CI: 4076.8–9268.8); V+D: c9786.6 (95%CI: 
7,124.7–12,448.5); L+D: c12,190.4 (95%CI: 8,693.2–15,687.7); pvalue < 0.001 
(Kruskal-Wallis). Cost-Effectiveness Incremental Ratios: c53,478.8 (D versus V+D) 
and −c6,639.5 (D versus L+D) per additional cured patient. Sensitivity analysis results: 
D versus V+D: D is efﬁ cient with lower costs (in 41.2%–77.9% of the simulations) 
and dominant (22.1%–38.0%); D versus L+D: D is dominant (44.6%–99.6%) and 
efﬁ cient with lower costs (0.4%–30.0%). CONCLUSIONS: Daptomycin as ﬁ rst-line 
therapy is mainly a dominant alternative when compared to daptomycin as rescue 
therapy after linezolid failure, showing better clinical results with lower associated 
costs. Daptomycin as ﬁ rst-line therapy does not show signiﬁ cant differences in effec-
tiveness when compared to daptomycin as rescue therapy after vancomycin failure, 
but it shows signiﬁ cantly lower costs.
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OBJECTIVES: Vaccination with the 23-valent pneumococcal polysaccharide vaccine 
(PPV23) is the current standard in Germany for diagnosis deﬁ ned risk groups (age 
5–59 years) and for seniors (≥60 years). a redeﬁ nition of this recommendation 
